| Covariate | Person 1 No consideration for hypoglycemia (w=0) High consideration for cost (w=1) |
Person1 Consideration for hypoglycemia (w=0.5) High consideration for cost (w=1) |
|---|---|---|
| Sex | Female | Female |
| Age | 47 | 47 |
| Race | Hispanic | Hispanic |
| SBP (mmHg) | 137 | 137 |
| Statin use | No | No |
| Anticoagulant use | No | No |
| BP medication use | No | No |
| Currently smoking | No | No |
| Oral diabetes medication use | No | No |
| Total cholesterol (mg/dL) | 188 (4.9 mmol/L) | 188 (4.9 mmol/L) |
| HDL cholesterol (mg/dL) | 44 (1.1 mmol/L) | 44 (1.1 mmol/L) |
| Hemoglobin A1c (%) | 7.5 (58.5 mmol/mol) | 7.5 (58.5 mmol/mol) |
| Serum creatinine (mg/DL) | 0.6 (53.0 μmol/L) | 0.6 (53.0 μmol/L) |
| Urine albumin creatinine ratio (mg/g) | 54.2 | 54.2 |
| CVD history | Yes | Yes |
| CVD risk (10-yr risk, %) | Low | Low |
| Myocardial infarction | 8 | 8 |
| Stroke | 2 | 2 |
| Microvascular risk (10-yr risk, %) | Low | Low |
| Nephropathy | 8 | 8 |
| Retinopathy | 6 | 6 |
| Neuropathy | 7 | 7 |
| Drug ranking score (95% CI) based on network meta-analysis12* | ||
| 1st | TZD 1.0 [0.89,1.28] |
SU 1.0 [0.95, 1.21] |
| 2nd | SU 0.98 [0.93, 1.37] |
TZD 0.97 [0.85, 1.25] |
| 3rd | SGLT-2-i 0.93 [0.81,1.25] |
SGLT-2-i 0.84 [0.81,1.08] |
| 4th | DPP-4-i 0.91 [0.77, 1.31] |
DPP-4-i 0.81 [0.73, 1.11] |
| 5th | GLP-1RA 0.82 [0.79, 1.32] |
GLP-1RA 0.63 [0.52, 1.01] |
| 6th | Basal insulin 0.49 [0.18, 1.63] |
Basal insulin 0.56 [0.32, 1.57] |
*
Drug ranking scores were normalized by the best ranking score. Score of 1 refers to the best ranking score, and the scores for other drugs are ranking scores relative the best ranking score. 95% confidence intervals were generated based on the uncertainty around the treatment effect estimates from the network meta-analysis.
TZD: Thiazolidinedione; SU: Sulfonylurea; GLP-1RA; GLP-1 agonist; SGLT-2-I; SGLT-2 inhibitor; DPP-4-I; DPP-4 inhibitor